Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Teladoc HealthSTU:4LL +2.22%51 EBITDA Margin % is 9.82% as of Jun. 2026. GuruFocus rates STU:4LL with a GF Score™ of 51/100 and a GF Value™ of €47.55 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 663 Healthcare Providers & Services companies, Teladoc Health ranks worse than 54.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Teladoc Health's EBITDA for the
three
months ended in Jun. 2026 was €52 Mil. Teladoc Health's Revenue for the
three
months ended in Jun. 2026 was €527 Mil. Therefore, Teladoc Health's EBITDA margin for the quarter that ended in Jun. 2026 was 9.82%.
Teladoc Health (STU:4LL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Teladoc Health EBITDA Margin % Related Terms
Teladoc Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Teladoc Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4LL vs OMCL, OMDA, CERT: EBITDA Margin % Comparison
For the Health Information Services subindustry, Teladoc Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teladoc Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Teladoc Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Teladoc Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teladoc Health (STU:4LL) has a EBITDA Margin % of 9.82% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Teladoc Health and its competitors. According to the industry distribution chart, Teladoc Health ranks #361 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 54.4%.
Is Teladoc Health's EBITDA Margin % too high?
Teladoc Health's current EBITDA Margin % is 9.82%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.23. Teladoc Health's value of 9.82% is 4% below this industry median. Based on the distribution chart, Teladoc Health ranks #361 out of 663 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Teladoc Health has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Teladoc Health's EBITDA Margin % compare to OMCL and OMDA?
According to the Healthcare Providers & Services industry distribution chart, Teladoc Health ranks #361 out of 663 companies for EBITDA Margin %. This places Teladoc Health in the lower half of its industry. The industry median EBITDA Margin % is 10.23. Teladoc Health's value of 9.82% is 4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.23, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teladoc Health's current EBITDA Margin % of 9.82% is 4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Teladoc Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teladoc Health's current EBITDA Margin % is 9.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teladoc Health stock overvalued right now?
Based on GuruFocus' analysis, Teladoc Health (STU:4LL) is currently considered Possible Value Trap. The stock's GF Value™ is €47.55, compared to a current price of €5.81 — trading 87.8% below its estimated fair value. The current EBITDA Margin % is 9.82% and 4% below the Healthcare Providers & Services industry median of 10.23. Teladoc Health's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Teladoc Health (STU:4LL), the current EBITDA Margin % is 9.82% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teladoc Health (STU:4LL) Overvalued in 2026?
Based on GuruFocus' analysis, Teladoc Health stock appears to be undervalued.
The current stock price of €5.81 is trading 87.8% below its estimated GF Value™ of €47.55.
GuruFocus considers Teladoc Health to be Possible Value Trap.
Key valuation signals for STU:4LL:
EBITDA Margin %: 9.82%
GF Value™: €47.55 vs. price of €5.81 (87.8% below fair value)
Industry Position: 4% below the Healthcare Providers & Services median (#361 of 663)
No single metric tells the full story. See the STU:4LL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
51GF Score
Get the complete analysis for STU:4LL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4LL has been successfully added to your 
